Clinical Trial Update: A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2, single-arm multicenter exploratory study evaluating perioperative TACE with iparomlimab, tuvonralimab (QL1706), and lenvatinib for resectable hepatocel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• QL1706
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Hepatocellular Carcinoma, Immunotherapy | Phase 2 | Status: NOT_YET_RECRUITING